

<b>Eribulin</b>	<b>Date:</b>	<b>2022-09-27</b>
	<b>Revision date:</b>	<b>-</b>
<b>1.8 Information Relating to Pharmacovigilance</b>	<b>Version no.:</b>	<b>0.1</b>
<b>1.8.2 Risk Management Plan</b>	<b>Page:</b>	<b>11/15</b>

---

## **PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN**

### **Summary of risk management plan for Eribulin medac (eribulin mesilate)**

This is a summary of the risk management plan (RMP) for Eribulin medac. The RMP details important risks of Eribulin medac, and how more information will be obtained about Eribulin medac's risks and uncertainties (missing information).

Eribulin medac's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Eribulin medac should be used.

Important new concerns or changes to the current ones will be included in updates of Eribulin medac's RMP.

### **I. The medicine and what it is used for**

Eribulin medac is authorised for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease, and for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease (see SmPC for the full indication). It contains eribulin mesilate as the active substance and it is given intravenously.

### **II. Risks associated with the medicine and activities to minimise or further characterise the risks**

Important risks of Eribulin medac, together with measures to minimise such risks and the proposed studies for learning more about Eribulin medac's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size – the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status – the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse events is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

## II.A List of important risks and missing information

Important risks of Eribulin medac are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Eribulin medac. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

List of important risks and missing information	
Important identified risks	Peripheral neuropathy Tachycardia Disseminated intravascular coagulation
Important potential risks	Adverse pregnancy outcomes Male infertility Gastrointestinal perforation
Missing information	None

## II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

## II.C Post-authorisation development plan

### *II.C.1 Studies which are conditions of the marketing authorisation*

There are no studies which are conditions of the marketing authorisation or specific obligation of Eribulin medac.

### *II.C.2 Other studies in the post-authorisation development plan*

There are no studies required for Eribulin medac.